Haplotype-Based Analysis of Genes Associated With Risk of Adverse Skin Reactions After Radiotherapy in Breast Cancer Patients

2007 ◽  
Vol 69 (3) ◽  
pp. 685-693 ◽  
Author(s):  
Tomo Suga ◽  
Atsuko Ishikawa ◽  
Masakazu Kohda ◽  
Yoshimi Otsuka ◽  
Shigeru Yamada ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Skin Reactions

Skin dose assessment with treatment planning system (TPS) and skin reaction evaluation of early breast cancer patients treated via an intraoperative radiation therapy (IORT) device

2018 ◽  
Vol 17 (4) ◽  
pp. 417-421
Author(s):  
Omid Baziar ◽  
Hamid Gholamhosseinian ◽  
Mohammad Naser Forghani
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Planning System ◽  
Treatment Planning System ◽  
Intraoperative Radiation Therapy ◽  
Skin Dose ◽  
Breast Cancer Patients ◽  
Skin Reactions ◽  
Intraoperative Radiation ◽  
Skin Doses

AbstractPurposeTo assess skin dose and incidence of skin reactions in early breast cancer patients treated via Intrabeam™ intraoperative radiation therapy (IORT) device.Materials and methodsIn total, 250 breast cancer patients treated with a single fraction of 20 Gy using 50 kV photon were recruited. The applicator to skin distance (ASD) was measured before the initiation of the radiation and the skin dose in each patient was accordingly calculated based on the treatment planning system (TPS).ResultsThe average skin doses calculated were equal to 7·91, 5·83, 3·96 and 2·14 Gy for 6–10, 10–15, 15–20 and 20–30 mm ASD values, respectively. It is noticeable that the skin doses could be lower than the TPS measurements up to 45%, mostly due to lack of backscatter radiation in breast tissue compared with the full scatter condition in the Zeiss water phantom. Finally, only three patients showed low-grade skin reactions 1 week after IORT. A review of the related literature also revealed the incidence of lower skin complications among patients treated via Intrabeam™ compared with MammoSite™ machine.ConclusionsThe Intrabeam™ TPS did not seem to be very reliable for accurate skin dosimetry. However, breast cancer treatment using Intrabeam™ could result in fewer incidences of skin reactions than MammoSite™ machine.

scholarly journals An evaluation of the skincare management of patients receiving radiotherapy for breast cancer

2019 ◽  
Vol 19 (4) ◽  
pp. 365-369 ◽  
Author(s):  
Leona McAlinden ◽  
Andrea Mullan ◽  
Paul Shepherd
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Best Practice ◽  
Management Strategies ◽  
Breast Cancer Patients ◽  
Skin Reactions ◽  
Prophylactic Measures ◽  
Radiation Induced ◽  
Guidance Needs ◽  
The Uk

AbstractAim:Breast cancer patients experience skin reactions during radiotherapy. Radiation-induced skin reactions can result in treatment delivery being interrupted. The aim of this paper is to evaluate the skincare management of patients receiving radiotherapy for breast cancer in order to inform best practice.Method:A literature search was undertaken using USearch and HONNI in support of the first-hand evidence gained from the supervised on-treatment review of patients receiving radiotherapy for breast cancer.Results:There is evidence to suggest that the skincare advice given to patients varies widely between departments in the UK with many not following nationally recommended guidelines. Studies demonstrate that there are ways to reduce skin reactions and that there are a range of effective management strategies being adopted. Prophylactic skincare has been explored to improve the resilience of the skin prior to commencing radiotherapy.Findings:Further investigation is required in order to clearly establish the optimum national skincare management for breast cancer patients. More studies are required to test the effectiveness and viability of prophylactic measures. Skincare guidance needs to be robustly developed and effectively promoted by therapeutic radiographers for radiotherapy patients to benefit from reduced, radiation-induced, skin reactions.

164: Influence of Double Strand Breaks Repair on Radiotherapy Induced Acute Skin Reactions in Breast Cancer Patients

2014 ◽  
Vol 110 ◽  
pp. S80-S81
Author(s):  
B.S.S. Rao ◽  
K.D. Mumbrekar ◽  
D.J. Fernandes ◽  
H.V. Goutham ◽  
K. Sharan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Double Strand Breaks ◽  
Breast Cancer Patients ◽  
Skin Reactions ◽  
Strand Breaks ◽  
Acute Skin Reactions

Feasibility of concurrent weekly paclitaxel and radiotherapy in adjuvant treatment of breast cancer: An experience from India.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11536-e11536
Author(s):  
Mohan Kumar Somashekar ◽  
Murali Subramanian V ◽  
Nirmala Srikantaiah S ◽  
Arul Ponni TR ◽  
Rajeev A G ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Conservative Surgery ◽  
Weekly Paclitaxel ◽  
Severe Toxicity ◽  
Breast Cancer Patients ◽  
Skin Reactions ◽  
Breast Conservative Surgery ◽  
Whole Breast Radiotherapy

e11536 Background: Majority of the breast cancer patients require adjuvant radiotherapy and chemotherapy for better locoregional and distant control. However the sequencing of these is still debatable . Hence concurrent chemo radiation may avoid the delay in either of the adjuvant therapies. Anthracyclines are not used concurrently with radiation because of severe toxicity. Hence the current study was taken to assess the feasibility of concurrent weekly paclitaxel and radiotherapy in adjuvant treatment of ca breast. Methods: A prospective study was conducted on 22 breast cancer patients, post modified radical mastectomy or breast conservative surgery from November 2008 to April 2010. Chest wall or whole breast radiotherapy was given on Tele Cobalt or Linac for a dose of 50 – 50.4Gy in conventional fractionation. Boost of 16 Gy was given to tumor cavity with photons or electrons for those undergone breast conservative surgery. All patients received Inj.paclitaxel 60 mg/m2 once a week for 5 weeks. After completion of RT, paclitaxel dose was increased to 80mg/m2 for remaining 7 cycles. This was followed by anthracycline based treatment sequentially as per standard adjuvant guidelines. Patients assessed weekly and toxicities graded based on CTC version 03. The minimum follow up was 2 months after completion of chemoradiation. Chi-Square test and Fisher exact test were used to interpret the results with literature. Results: See table below. Skin reaction was more frequent and severe of all toxicities (p=0.003).With available literatures on adjuvant radiation alone the grade III and higher skin reactions are 3% but in our study it is 28% because of which 5/22 (22%) patients had interruption of both chemotherapy and radiation. Conclusions: Concurrent chemoradiation with weekly paclitaxel in adjuvant treatment of ca breast is associated with more skin reactions which may result in significant treatment interruptions. It should be practiced cautiously which requires further randomized control studies to assess the toxicities in detail. [Table: see text]

An investigation into the use of a non-metallic deodorant during radiotherapy treatment: a randomised controlled trial

2009 ◽  
Vol 8 (1) ◽  
pp. 3-9 ◽  
Author(s):  
Claire Bennett
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Controlled Trial ◽  
Daily Routine ◽  
Breast Cancer Patients ◽  
Skin Reactions ◽  
The United Kingdom ◽  
Patient Groups ◽  
Group 2 ◽  
Randomised Controlled

AbstractIntroduction: Many patients in the United Kingdom having radiotherapy for breast cancer are recommended not to use a deodorant during treatment. The advice is not evidence based, it is solely thought as deodorants contained metals, which would react with radiation and cause an increased skin reaction. Hence this research was undertaken to establish whether patients having a course of radiotherapy for breast cancer could use a deodorant as part of their daily routine.Method: The research took place between May 2004 and February 2005. A total of 192 breast cancer patients were recruited. This included breast or chest-wall patients with or without axilla involvement. The study was designed with two groups. Group 1 used no deodorant and Group 2 a specific deodorant. The researcher reviewed patients weekly, assessing skin reactions and recording the researcher and patient's observations.Results: Most patients experienced no reaction or mild erythema and dry desquamation in the axilla. This was observed in both groups. Therefore, findings of this study indicate that future breast cancer patients should be given the choice of using this deodorant.Further recommendations: Test the reliability of the skin assessment form, extend the research to include other patient groups who have their axilla treated, test different deodorants.

Sign in / Sign up

Export Citation Format

Share Document